Korean J Infect Dis.
1998 Feb;30(1):69-74.
Immunogenicity and Safety of Recombinant Hepatitis B Vaccine(Engerix B)
- Affiliations
-
- 1Department of Pediatrics, College of Medicine, Hallym University, Kangwondo, Korea.
- 2Department of Microbiology, College of Medicine, Hallym University, Kangwondo, Korea.
- 3Department of Internal Medicine, College of Medicine, Hallym University, Kangwondo, Korea.
- 4Department of Clinical Pathololgy, College of Medicine, Hallym University, Kangwondo, Korea.
Abstract
- BACKGROUND
Several studies on the efficacy and safety of the hepatitis B vaccine have shown variable immunogenicity. In this study we reexamined the immunogenicity and safety of recombinant hepatitis B vaccine, Engerix B which have currently been administered to the children in Korea.
METHODS
Serum samples were collected from 126 children and 111 adults who were immunized according to the 0, 1, 2-month and 0, 1, 6-month vaccination schedule. Anti-HBs antibody titers were measured by ELISA in sera obtained after each immunization, and compared by immunization schedules.
RESULTS
In 62 children with 0, 1, 2-month immunization schedule seroconversion rate was 83.9% after 1st vaccination, 96.8% after 2nd, and 98.4% after 3rd. In 64 children with 0, 1, 6-month immunization schedule seroconversion rates was 78.1% after 1st vaccination, 87.5% after 2nd and 100% after 3rd. In 50 adults immunized with 0, 1, 2-month schedule seroconversionrates was 48.0% after 1st vaccination, 74.0% after 2nd and 90.0% after 3rd. In 61 adults immunized with 0, 1, 6-month schedule seroconversion rate was 44.3% after 1st vaccination, 65.6% after 2nd and 93.4% after 3rd. Seroconversion rate after 0, 1, 2- month vaccination schedule were 98.4% in children and 90.0% in adults. Seroconversion rate after 0, 1, 6-month schedule were 100% in children and 93.4% in adults. There were no significant local and systemic untoward reactions among vaccinees.
CONCLUSION
The recombinant Engerix B is excellent in immunogenicity with 93.4% and 100% seroconversion rates in adults and children, respectively. There is no significant difference in seroconversion rate between two vaccination schedule. The vaccine is safe.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Immunogenicity and reactogenicity of a yeast recombinant DNA hepatitis B vaccine in healthy subjects
- Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia
- Immunogenicity and Safety of Recombinant Hepatitis B Vaccine(HG-II®) in Healthy Infants and Children
- Original Articles: Immunogenicity and Safety of a 20 microgram Dose of the Green Cross Recombinant Hepatitis B Vaccine ( HG -II ) in Healthy Adults
- Immunogenicity of a Recombinant Hepatitis B Virus Vaccine Compared with a Plasma-derived Hepatitis B Vaccine and of Vaccination Schedules in Neonates
